← Back to Search

Treatment for Pancreatic Cancer (PRECEDE Trial)

N/A
Recruiting
Research Sponsored by Arbor Research Collaborative for Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 6 years
Awards & highlights

Summary

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Eligible Conditions
  • Pancreatic Cancer
  • Pancreatic Cysts
  • Genetic Predisposition

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 6 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 6 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Development of PDAC

Find a Location

Who is running the clinical trial?

Arbor Research Collaborative for HealthLead Sponsor
20 Previous Clinical Trials
25,467 Total Patients Enrolled
Diane Simeone, MDStudy ChairUC San Diego Moores Cancer Center
~6098 spots leftby Dec 2030
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top